Erratum: Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease (PLoS ONE (2014) 9, 6 (e98689) DOI: 10.1371/journal.pone.0098689);Factors affecting the accuracy of Controlled Attenuation Parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Jung, Kyu Sik ^a   Kim, Beom Kyung ^a,b   Kim, Seung Up ^a,b   Chon, Young Eun ^a   Cheon, Kyung Hyun ^a   Kim, Sung Bae ^a   Lee, Sang Hoon ^d   Ahn, Sung Soo ^a   Park, Jun Yong ^a,b   Kim, Do Young ^a,b   Ahn, Sang Hoon ^a,b,c   Park, Young Nyun ^a   Han, Kwang Hyub ^a,b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

^c Yonsei University   (South Korea)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC LIVER DISEASE; CONTROLLED ATTENUATION PARAMETER; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELASTOGRAPHY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NECROINFLAMMATION; PROSPECTIVE STUDY; SOUTH KOREA; THROMBOCYTE COUNT; TRANSIENT ELASTOGRAPHY; ADOLESCENT; BIOPSY; BLOOD ANALYSIS; COMPLICATION; LIVER DISEASES; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BLOOD CHEMICAL ANALYSIS; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84902513255     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107331     Document Type: Erratum

References (34)

1. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med. 346: 1221-1231.
2. Oh MK, Winn J, Poordad F (2008) Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 28: 503-522. doi: 510.1111/j.1365-2036.2008.03752.x. Epub 02008 Jun 03753.
3. Yilmaz Y (2012) Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther. 36: 815-823. doi: 810.1111/apt.12046.
4. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, et al. (2002) Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 35: 1485-1493. (Pubitemid 34966903)
5. Ong JP, Pitts A, Younossi ZM (2008) Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 49: 608-612. Epub 2008 Jul 2009.
6. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, et al. (2006) Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 130: 1636-1642.
7. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, et al. (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 38: 75-85. (Pubitemid 36775798)
8. Spitzer AL, Lao OB, Dick AA, Bakthavatsalam R, Halldorson JB, et al. (2010) The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl. 16: 874-884. doi: 810.1002/lt.22085.
9. de Meijer VE, Kalish BT, Puder M, Ijzermans JN (2010) Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg. 97: 1331-1339. doi: 1310.1002/bjs.7194.
10. Dowman JK, Tomlinson JW, Newsome PN (2011) Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 33: 525-540. doi: 510.1111/j.1365-2036. 2010.04556.x. Epub 02010 Dec 04529.
11. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 128: 1898-1906. (Pubitemid 40824701)
12. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, et al. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 97: 2614-2618.
13. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, et al. (2009) Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 51: 433-445. Epub 2009 Jun 2011.
14. Boursier J, Cales P (2012) Controlled attenuation parameter (CAP): a new device for fast evaluation of liver fat? Liver Int. 32: 875-877. doi: 810.1111/j.1478-3231.2012.02824.x.
15. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, et al. (2010) Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 36: 1825-1835. Epub 2010 Sep 1827.
16. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, et al. (2012) Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 32: 902-910. doi: 910.1111/j.1478-3231.2012.02781.x. Epub 02012 Mar 02721.
17. de Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B (2012) Noninvasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 32: 911-918. doi: 910.1111/j.1478-3231.2012.02820.x.
18. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, et al. (2012) Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J Viral Hepat. 19: 244-253. doi: 210.1111/j.1365-2893.2011.01534.x. Epub 02011 Oct 01513.
19. Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, et al. (2009) Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology. 49: 1083-1089. doi: 1010.1002/hep.22748.
20. Myers RP, Crotty P, Pomier-Layrargues G, Ma M, Urbanski SJ, et al. (2010) Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy. Liver Int. 30: 1471-1480. doi: 1410.1111/j.1478-3231.2010.02331.x. Epub 02010 Aug 02330.
21. Kim SU, Seo YS, Cheong JY, Kim MY, Kim JK, et al. (2010) Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. Aliment Pharmacol Ther. 32: 498-505. doi: 410.1111/j.1365-2036.2010.04353.x. Epub 02010 May 04311.
22. Kim SU, Kim JK, Park YN, Han KH (2012) Discordance between liver biopsy and Fibroscan(R) in assessing liver fibrosis in chronic hepatitis b: risk factors and influence of necroinflammation. PLoS One. 7: e32233. doi: 32210.31371/journal.pone.0032233. Epub 0032012 Feb 0032223.
23. Chon YE, Jung KS, Kim SU, Park JY, Park YN, et al. (2014) Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 34: 102-109.
24. Mederacke I, Wursthorn K, Kirschner J, Rifai K, Manns MP, et al. (2009) Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int. 29: 1500-1506. doi: 1510.1111/j.1478- 3231.2009.02100.x. Epub 02009 Sep 02103.
25. (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 20: 15-20.
26. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 94: 2467-2474. (Pubitemid 29420675)
27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41: 1313-1321. (Pubitemid 40770284)
28. Kim SU, Kim do Y, Park JY, Lee JH, Ahn SH, et al. (2010) How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B? J Clin Gastroenterol. 44: 66-71. doi: 10.1097/MCG.1090b1013e3181a1095c1097f.
29. Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, et al. (2008) Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 47: 380-384. (Pubitemid 351280705)
30. Chon YE, Choi EH, Song KJ, Park JY, Kim do Y, et al. (2012) Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One. 7: e44930. doi: 44910.41371/journal.pone.0044930. Epub 0042012 Sep 0044925.
31. El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, et al. (2009) Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg. 250: 691-697. doi: 610.1097/SLA.1090b1013e3181bcd1096dd.
32. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, et al. (2009) Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol. 7: 227-233. doi: 210.1016/j.cgh.2008.1010.1023. Epub 2008 Oct 1030.
33. Kim SU, Han KH, Park JY, Ahn SH, Chung MJ, et al. (2009) Liver stiffness measurement using FibroScan is influenced by serum total bilirubin in acute hepatitis. Liver Int. 29: 810-815. doi: 810.1111/j.1478-3231.2008.01894.x. Epub 02008 Oct 01824.
34. Kumar M, Rastogi A, Singh T, Behari C, Gupta E, et al. (2013) Controlled Attenuation Parameter for Non-invasive Assessment of Hepatic Steatosis: Does aetiology affect performance. J Gastroenterol Hepatol 21: 12134.